{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:12:27Z","timestamp":1783761147293,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,11]]},"DOI":"10.7759\/cureus.112442","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:26:54Z","timestamp":1783758414000},"source":"Crossref","is-referenced-by-count":0,"title":["Unmasking Refractory Hypothyroidism: Persistent Iron-Levothyroxine Interaction Despite Appropriate Dose Separation"],"prefix":"10.7759","author":[{"given":"Zalatt Pann","family":"Ei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaw Tar","family":"Soe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaung Htet","family":"Kyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu Wai","family":"Phyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyan Tun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12824","article-title":"Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee","volume":"84","author":"Okosieme O","year":"2016","unstructured":"Okosieme O, Gilbert J, Abraham P, et al.. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin Endocrinol (Oxf). 2016, 84:799-808. 10.1111\/cen.12824","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor PN","year":"2018","unstructured":"Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018, 14:301-16. 10.1038\/nrendo.2018.18","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000003","article-title":"When thyroid hormone replacement is ineffective?","volume":"20","author":"Benvenga S","year":"2013","unstructured":"Benvenga S. When thyroid hormone replacement is ineffective?. Curr Opin Endocrinol Diabetes Obes. 2013, 20:467-77. 10.1097\/MED.0000000000000003","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.621616","article-title":"Levothyroxine therapy in gastric malabsorptive disorders","volume":"11","author":"Virili C","year":"2020","unstructured":"Virili C, Brusca N, Capriello S, Centanni M. Levothyroxine therapy in gastric malabsorptive disorders. Front Endocrinol (Lausanne). 2020, 11:621616. 10.3389\/fendo.2020.621616","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/aot-2025-7","article-title":"Drug administration as a factor affecting levothyroxine therapy\u2014results of the CONTROL Surveillance II study","volume":"10","author":"Cummings-John D","year":"2025","unstructured":"Cummings-John D, Sandulli W, Castano M, et al.. Drug administration as a factor affecting levothyroxine therapy\u2014results of the CONTROL Surveillance II study. Ann Thyroid. 2025, 10:4. 10.21037\/aot-2025-7","journal-title":"Ann Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_525_24","article-title":"Levothyroxine administration techniques audit and utility of its assessment at each visit: a hospital-based mixed model study","volume":"29","author":"Singh R","year":"2025","unstructured":"Singh R, Tandon A. Levothyroxine administration techniques audit and utility of its assessment at each visit: a hospital-based mixed model study. Indian J Endocrinol Metab. 2025, 29:567-72. 10.4103\/ijem.ijem_525_24","journal-title":"Indian J Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12559","article-title":"Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS)","volume":"82","author":"Irving SA","year":"2015","unstructured":"Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015, 82:136-41. 10.1111\/cen.12559","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.005","article-title":"Factors affecting gastrointestinal absorption of levothyroxine: a review","volume":"39","author":"Skelin M","year":"2017","unstructured":"Skelin M, Lucijani\u0107 T, Amid\u017ei\u0107 Klari\u0107 D, et al.. Factors affecting gastrointestinal absorption of levothyroxine: a review. Clin Ther. 2017, 39:378-403. 10.1016\/j.clinthera.2017.01.005","journal-title":"Clin Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag024","article-title":"Beyond the Gut: thyroxine malabsorption, pharmacokinetics, and delivery","volume":"111","author":"Law LS","year":"2026","unstructured":"Law LS, Kuu NW, Leong MH, Lo EA, Yeoh SF, Yang SP. Beyond the Gut: thyroxine malabsorption, pharmacokinetics, and delivery. J Clin Endocrinol Metab. 2026, 111:1203-11. 10.1210\/clinem\/dgag024","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83123","article-title":"Managing levothyroxine malabsorption in refractory hypothyroidism: a case report","volume":"17","author":"Rashwan G","year":"2025","unstructured":"Rashwan G, Jumani A, Ibrahim H, AlNajjar M. Managing levothyroxine malabsorption in refractory hypothyroidism: a case report. Cureus. 2025, 17:e83123. 10.7759\/cureus.83123","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1386510","article-title":"Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose","volume":"15","author":"Ferrari SM","year":"2024","unstructured":"Ferrari SM, Patrizio A, Mazzi V, et al.. Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose. Front Endocrinol (Lausanne). 2024, 15:1386510. 10.3389\/fendo.2024.1386510","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref12","unstructured":"Manchester University NHS Foundation Trust. Levothyroxine Absorption Test Protocol (Adults). (2023). Accessed. April 10, 2026: https:\/\/mft.nhs.uk\/app\/uploads\/2023\/03\/Levothyroxine-Absorption-Test-Adults.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485572-unmasking-refractory-hypothyroidism-persistent-iron-levothyroxine-interaction-despite-appropriate-dose-separation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:26:55Z","timestamp":1783758415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485572-unmasking-refractory-hypothyroidism-persistent-iron-levothyroxine-interaction-despite-appropriate-dose-separation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.112442","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}